The aim of this study was to develop and assess the therapeutic action, in the event of renal dysfunctions against type II diabetic rats by scopoletin-loaded solid lipid nanoparticles (S-SLN). Streptozotocin (55 mg / kg) for control of diabetes was used in the experimental regimen. Rat has been divided into different classes and treated for six weeks with SLNs loaded with scopoletin (25mg/kg). Weight of the tissue, biochemical parameters such as cytokines pro-inflammatory. The Nuclear Transcriptions Factor-kappa B (NF-kB) and NADPH oxidase 4 is indicators of TNF-α, IL-1β and IL-6 inflammatory mediator PGE2. Dose-dependent decrease in blood glucose level (44%) was observed in Scopoletin loaded SLNs along with increase in body weight (11%) and plasma insulin level in 41%. In addition to this, treatments were shown at TNF-α-levels (53%), IL1β-level (42%), IL-6-level (35%), PGE2-level (47%), NF-kB-level (31%), and NADPH-oxidase-inhibited 4 levels. The histopathology suggested reduced blood vessels and inflammatory vessels. Overall, the study interpreted the fact that scopoletin-loaded SLNs effectively inhibited the growth of nephropathy by targeting inflammatory pathways in STZ induced type-II diabetic rats.